SageView Advisory Group LLC Purchases New Holdings in Kenvue Inc. (NYSE:KVUE)

SageView Advisory Group LLC bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,581 shares of the company's stock, valued at approximately $333,000.

Several other large investors also recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Kenvue in the 4th quarter valued at $521,348,000. Franklin Resources Inc. lifted its position in shares of Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after buying an additional 10,682,003 shares during the last quarter. Boston Partners boosted its stake in shares of Kenvue by 36.9% during the 4th quarter. Boston Partners now owns 23,595,963 shares of the company's stock worth $503,145,000 after acquiring an additional 6,366,097 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Kenvue during the 4th quarter valued at about $98,926,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of NYSE KVUE traded up $0.69 during trading hours on Friday, reaching $23.42. The stock had a trading volume of 22,595,142 shares, compared to its average volume of 17,088,173. The company has a market cap of $44.93 billion, a price-to-earnings ratio of 44.19, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The business's fifty day moving average is $22.91 and its two-hundred day moving average is $22.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the subject of a number of recent analyst reports. Citigroup upped their target price on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Evercore ISI assumed coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Finally, Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.